Girolamo Caló, Olivier Civelli, Rainer K. Reinscheid, Chiara Ruzza
{"title":"GtoPdb v.2023.1中的神经肽S受体","authors":"Girolamo Caló, Olivier Civelli, Rainer K. Reinscheid, Chiara Ruzza","doi":"10.2218/gtopdb/f44/2023.1","DOIUrl":null,"url":null,"abstract":"The neuropeptide S receptor (NPS receptor) responds to the 20 amino-acid peptide neuropeptide S derived from a precursor (NPS, P0C0P6). NPS activates its receptor at low nanomolar concentrations elevating intracellular cAMP and calcium levels [71]. Currently, some peptidic and small molecule NPS receptor antagonists are available as research tools [27, 79, 8, 59]. No NPS receptor ligands are currently used clinically.","PeriodicalId":14617,"journal":{"name":"IUPHAR/BPS Guide to Pharmacology CITE","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neuropeptide S receptor in GtoPdb v.2023.1\",\"authors\":\"Girolamo Caló, Olivier Civelli, Rainer K. Reinscheid, Chiara Ruzza\",\"doi\":\"10.2218/gtopdb/f44/2023.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The neuropeptide S receptor (NPS receptor) responds to the 20 amino-acid peptide neuropeptide S derived from a precursor (NPS, P0C0P6). NPS activates its receptor at low nanomolar concentrations elevating intracellular cAMP and calcium levels [71]. Currently, some peptidic and small molecule NPS receptor antagonists are available as research tools [27, 79, 8, 59]. No NPS receptor ligands are currently used clinically.\",\"PeriodicalId\":14617,\"journal\":{\"name\":\"IUPHAR/BPS Guide to Pharmacology CITE\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IUPHAR/BPS Guide to Pharmacology CITE\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2218/gtopdb/f44/2023.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IUPHAR/BPS Guide to Pharmacology CITE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2218/gtopdb/f44/2023.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The neuropeptide S receptor (NPS receptor) responds to the 20 amino-acid peptide neuropeptide S derived from a precursor (NPS, P0C0P6). NPS activates its receptor at low nanomolar concentrations elevating intracellular cAMP and calcium levels [71]. Currently, some peptidic and small molecule NPS receptor antagonists are available as research tools [27, 79, 8, 59]. No NPS receptor ligands are currently used clinically.